Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $75.6 million.

  • Viking Therapeutics' Cash from Investing Activities rose 104842.04% to $75.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $341.4 million, marking a year-over-year increase of 16169.3%. This contributed to the annual value of $341.4 million for FY2025, which is 16169.3% up from last year.
  • Latest data reveals that Viking Therapeutics reported Cash from Investing Activities of $75.6 million as of Q4 2025, which was up 104842.04% from $160.0 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year Cash from Investing Activities high stood at $160.0 million for Q3 2025, and its period low was -$459.8 million during Q1 2024.
  • Its 5-year average for Cash from Investing Activities is -$14.9 million, with a median of $10.4 million in 2021.
  • Per our database at Business Quant, Viking Therapeutics' Cash from Investing Activities plummeted by 2101865.33% in 2024 and then surged by 104842.04% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Cash from Investing Activities stood at $27.4 million in 2021, then plummeted by 73.51% to $7.3 million in 2022, then skyrocketed by 392.19% to $35.7 million in 2023, then crashed by 81.57% to $6.6 million in 2024, then surged by 1048.42% to $75.6 million in 2025.
  • Its Cash from Investing Activities stands at $75.6 million for Q4 2025, versus $160.0 million for Q3 2025 and $42.5 million for Q2 2025.